



1st Quarter Financial Results for FYE/Mar 2009

Terumo Corporation

30, July 2008

Growth trend steady in spite of NHI price down and impact of foreign exchange

(Unit: Billion yen)

	Q1 FYE/Mar. 2008	Q1 FYE/Mar. 2009	Rate of change
Net Sales	75.5	77.8	3%
Gross profit (%)	41.5 (55.0%)	42.2 (54.3%)	2%
S.G.A Expenses (%)	24.5 (32.5%)	26.0 (33.4%)	6%
Operating Income (%)	17.0 (22.5%)	16.2 (20.9%)	-4%
Ordinary Income (%)	18.6 (24.6%)	18.9 (24.2%)	1%
Net Income	13.1	14.0	7%

Average exchange rate


US\$ 121 yen
EUR 163 yen

105 yen
163 yen


13.5% yen appreciation
0.4% yen depreciation

Net Sales (by Region)

(Unit: Billion yen)




Net Sales (by Product Group)



S.G.A Expenses

(Unit: Billion yen)




**S.G.A Expenses ratio
0.9 point increase**

	Q1 FYE/Mar. 2008	Q1 FYE/Mar. 2009	Change	% change
Personnel	9.3	9.6	0.3	4.1%
Logistics	2.1	2.3	0.2	7.5%
Sales promotion & advertising	2.3	2.5	0.2	7.1%
R&D	3.8	3.8	-	-1.9%
Others	7.0	7.8	0.8	12.3%
Total	24.5	26.0	1.5	6.1%

The impact of external factors

(Unit: Billion yen)



Growth steady on truck for annual forecast

(Unit: Billion yen)

	FYE/Mar 2009 Q1 Results	FYE/Mar. 2009 Annual Forecast
Net Sales	77.8	318.0
Operating Income (%)	16.2 (20.9%)	68.0 (21.4%)
Ordinary Income (%)	18.9 (24.2%)	68.0 (21.4%)
Net Income	14.0	45.0


Average exchange
rate

US\$ 105 yen
EUR 163 yen

100 yen
155 yen



Topics



Costs increasing due to soaring material prices, transportation charges and new regulations in Japan

◆ Steep price rise of plastic materials & I.V. substances

- PP, PE Packaging material & amino acids

◆ Increase in transportation charges

- Ocean freight (for exports)
- Storage in Japan

◆ New regulation in Japan

(amended Pharmaceutical Affairs Law)

- Indication of specification, material and packing material changes

Strengthen the growth of the interventional business

PTCA balloon catheter


Hiryu (Oct. 2007 launched)



19%
(Sep. 2007) → **28%**
(Jun. 2008)

Ultrasound diagnostic catheter

ViewIT (Apr. 2008 launched)




12%
(Mar. 2008) → **20%**
(Mar. 2009 forecast)


※ Transition in Japanese share of PTCA balloon and ultrasound diagnostic catheters (Terumo estimate)

10

Acquired all shares of Clinical Supply Co., Ltd.


- Strengthen radiology business in Japan
- Globally deploy Clinical Supply products
- New product development taking advantage of the strengths of Terumo and Clinical Supply

 株式会社 クリニカル・サプライ



Micro catheter

(Treatment of liver cancer, etc.)




Angiographic catheter

Europe driving growth

- ◆ Interventional products in particular seeing large sales growth

Sales of Interventional products in Europe



Further enhancement of the product line-up in Europe

◆ Peripheral stent “Misago”

- Released in January 2008
- Expanding applications of stents to domains other than the heart



Treatment for femoral artery and other obtrusions

◆ Automatic centrifugal separation system, “TACSI”


- Launch to go into full effect from October 2008
- High value added blood transfusion systems



13

Sales of blood transfusion systems steadily expanding

- ◆ Japanese apheresis equipment, “TERUSYS” enjoying favorable sales
- ◆ Sales of sterile tube connecting devices (TSCD) increasing
- ◆ Increasing demand for blood bags in Asia, showing high growth rates in India and the Middle East



Booth at the general assembly of International Society Blood Transfusion (ISBT): Macao, June 2008

Global development making steady progress

◆ 「Nobori」

- Europe: 3,000 post-marketing clinical trials started
Announced at academic conference (Euro PCR)
- Japan: Clinical tests still in progress



Nobori, Drug eluting stent

◆ 「DuraHeart」

- The U.S.: University of Michigan in preparation for implant
- Japan: Clinical tests will start in this fiscal year



The patient of
DuraHeart, LVAS
(the right) 15

◆ 「Anaconda」

- The U.S. : FDA approved the shift to phase II of clinical tests



The mid-term management plan started as planned



IR Contact

TERUMO Corporation

Corporate Communication (IR) Dept.

E-mail: CCD@terumo.co.jp

This document contains forward-looking statements that reflect management's current views with respect to certain future events and financial performance. Actual results may differ materially from those projected or implied in the forward-looking statements and from historical trends. Furthermore, certain forward-looking statements are based upon assumptions of future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those projected or implied in any forward-looking statements include, but are not limited to, changes in overall economic conditions, fluctuations of foreign exchange rates, and intensifying price competition in the markets for our products.